Thrombophilia Due to Thrombomodulin Defect Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Thrombophilia Due to Thrombomodulin Defect. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Thrombophilia Due to Thrombomodulin Defect receives a directional score of 68/100, combining unmet need (86/100), competitive intensity (79/100) and market attractiveness (80/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

A rare genetic coagulation disorder characterised by marked bleeding tendency and posttraumatic bleeding with easy bruising, soft tissue and muscle bleeding, haemarthroses and menorrhagia. Caused by an increase of soluble thrombomodulin in plasma with subsequent protein C activation and reduction of thrombin generation within a potential thrombus. Abnormal laboratory findings include markedly elevated plasma thrombomodulin, reduced prothrombin consumption and decreased thrombin generation.

The reproducible record is Patsnap disease ID fb625294ba9c4673a04dbc067bc7e7ff and MeSH identifier C566057. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: Heart Disease and Stroke Statistics—2022 Update Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association

• FVL is the most common inherited thrombophilia in populations of European descent (prevalence, 5.2%) but is rare in African (1.2%) and Asian (0.45%) populations.39 In ARIC, ≈5% of White and <1% of Black people were heterozygous carriers of FVL, and lifetime risk of VTE was 17.1% in indi­ viduals with the FVL genetic variant.11 Pooling data from 36 epidemiological studies showed that risk of VTE was increased 4-fold in people with heterozy­ gous FVL (OR, 4.2 [95% CI, 3.4–5.3]) and 11-fold in those with homozygous FVL (OR, 11.4 [95% CI, 6.8–19.3]) compared with noncarriers.40 • Antithrombin deficiency is a rare variant that is associated with greatly increased risk of incident VTE (OR, 14.0 [95% CI, 5.5–29.0]).41 A bayesian meta-analysis found that for childbearing females with this variant, VTE risk was 7% in the antepartum period and 11% postpartum.42 • Whole-exome sequencing of a panel of 55 throm­ bophilia genes in 64 patients with VTE identified a probable disease-causing genetic variant or vari­ ant of unknown significance in 39 of 64 individuals (60.9%).43 • More common genetic variants associated with VTE have a lesser risk of VTE than rare vari­ ants and include non-O blood group, prothrom­ bin 20210A, and sickle cell disease and trait.44 GWASs have identified additional common genetic variants associated with VTE risk, includ­ ing variants in F5, F2, F11, FGG, and ZFPM2.45 These common variants individually increase the risk of VTE to a small extent, but a GRS composed of a combination of common variants yielded an OR for VTE risk of 7.5.46

Review source

Epidemiology evidence 2: Heart Disease and Stroke Statistics—2025 Update 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

• Antithrombin deficiency is a rare disease (preva- lence, 0.02%–0.2%) that is associated with greatly increased risk of incident VTE (OR, 14.0 [95% CI, 5.5–29.0]).48 A Bayesian meta-analysis found that for childbearing females with this variant, VTE risk was 7% in the antepartum period and 11% postpartum.49 • Whole-exome sequencing of a panel of 55 throm- bophilia genes in 64 patients with VTE identified a probable disease-causing genetic variant or vari- ant of unknown significance in 39 of 64 individuals (60.9%).50 • GWASs have identified additional common genetic variants associated with VTE risk, including vari- ants in F5, F2, F11, FGG, and ZFPM2.51 These common variants individually increase the risk of VTE to a small extent, but a GRS composed of a combination of 5 common variants yielded an OR for VTE risk of 7.5.52 • Exome-wide analysis of rare variants in >24 000 individuals of European ancestry and 1858 individu- als of African ancestry confirmed previously impli- cated loci but did not uncover rare novel variants associated with VTE. Similarly, targeted sequenc- ing efforts did not uncover rare novel variants for DVT. However, multiancestry genome-wide GWAS meta-analyses have established >30 novel VTE risk loci.53,54 • A GRS including 1 092 045 SNPs was associated with higher odds of incident VTE event (OR, 51% per 1-SD increase in GRS).54 The risk of VTE in the higher tail end of this GRS was similar to that attrib- uted to monogenic VTE variants. This GRS may guide decision-making on which individuals may benefit from anticoagulant therapy. Prevention • Pharm

Review source

Epidemiology evidence 3: Heart Disease and Stroke Statistics—2021 Update

38. Zöller B, Ohlsson H, Sundquist J, Sundquist K. Familial risk of venous thromboembolism in first-, second- and third-degree relatives: a nation- wide family study in Sweden. Thromb Haemost. 2013;109:458–463. doi: 10.1160/TH12-10-0743 39. Kujovich JL. Factor V Leiden thrombophilia. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, eds. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle; 1993–2020. 40. Simone B, De Stefano V, Leoncini E, Zacho J, Martinelli I, Emmerich J, Rossi E, Folsom AR, Almawi WY, Scarabin PY, et al. Risk of venous throm- boembolism associated with single and combined effects of factor V Leiden, prothrombin 20210A and methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013;28:621–647. doi: 10.1007/s10654-013-9825-8 41. Croles FN, Borjas-Howard J, Nasserinejad K, Leebeek FWG, Meijer K. Risk of venous thrombosis in antithrombin deficiency: a systematic review and bayesian meta-analysis. Semin Thromb Hemost. 2018;44:315–326. doi: 10.1055/s-0038-1625983 42. Croles FN, Nasserinejad K, Duvekot JJ, Kruip MJ, Meijer K, Leebeek FW. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: sys- tematic review and bayesian meta-analysis. BMJ. 2017;359:j4452. doi: 10.1136/bmj.j4452 43. Morange PE, Suchon P, Trégouët DA. Genetics of venous thrombosis: update in 2015. Thromb Haemost. 2015;114:910–919. doi: 10.1160/ TH15-05-0410 44. Klarin D, Emdin CA, Natarajan P, Conrad MF, INVENT Consortium, Kathiresan S. Genetic analysis of ven

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Thrombophilia Due to Thrombomodulin Defect, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Thrombophilia Due to Thrombomodulin Defect thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: C5

Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:6554279). Activated downstream of classical, alternative, lectin and GZMK complement pathways (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:39914456, PubMed:39814882, PubMed:6554279). Component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis (PubMed:26841837, PubMed:27052168, PubMed:30552328, PubMed:30643019). Complement C5b is generated following cleavage by C5 convertase and initiates formation of the MAC complex: C5b binds sequentially C6, C7, C8 and multiple copies of the pore-forming subunit C9 (PubMed:30552328, PubMed:30643019). During MAC complex assembly, the C5b6 subcomplex, composed of complement C5b and C6, associates with the outer leaflet of target cell membrane, reducing the energy for membrane bending (PubMed:30552328, PubMed:32569291). Mediator of local inflammatory process released following cleavage by C5 convertase (PubMed:8182049, PubMed:9553099). Acts by binding to its receptor (C5AR1 or C5AR2), activating G protein-coupled receptor signaling and inducing a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:36806352, PubMed:37852260, PubMed:37169960, PubMed:8182049, PubMed:9553099). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation (PubMed:342601, PubMed:37852260, PubMed:37169960, PubMed:5765461, PubMed:8182049, PubMed:9553099).

The mechanism anchor is C5, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 406 registered studies.

• NCT07741630 — Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer; Not yet recruiting; Phase 2; sponsor Peking University Third Hospital; enrollment 20.
• JPRN-UMIN000062446 — A single-center retrospective study on clinical outcomes after the introduction of caplacizumab for thrombotic thrombocytopenic purpura and an exploratory analysis of risk factors for the ADAMTS13 inhibitor boosting; 参加者募集終了‐試験継続中/No longer recruiting; Not Applicable; sponsor not stated; enrollment 12.
• NCT07630415 — EARLY DIAGNOSIS OF SEPTIC DIC (EASY-DIC); Not yet recruiting; Not Applicable; sponsor Les Hopitaux Universitaires de Strasbourg; enrollment 492.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering or broader asset-level indexing; add target and asset searches before valuation.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate C5 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Thrombophilia Due to Thrombomodulin Defect merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Thrombophilia Due to Thrombomodulin Defect is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.